DK1430047T3 - Substituerede alkylaminopyridazinonderivater, fremgangsmåde til fremstilling deraf og en farmaceutisk sammensætning indeholdende disse - Google Patents
Substituerede alkylaminopyridazinonderivater, fremgangsmåde til fremstilling deraf og en farmaceutisk sammensætning indeholdende disseInfo
- Publication number
- DK1430047T3 DK1430047T3 DK02762620T DK02762620T DK1430047T3 DK 1430047 T3 DK1430047 T3 DK 1430047T3 DK 02762620 T DK02762620 T DK 02762620T DK 02762620 T DK02762620 T DK 02762620T DK 1430047 T3 DK1430047 T3 DK 1430047T3
- Authority
- DK
- Denmark
- Prior art keywords
- sub
- hydrogen
- stands
- alkyl
- carbon atoms
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 125000004432 carbon atom Chemical group C* 0.000 abstract 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 150000002431 hydrogen Chemical class 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 239000002249 anxiolytic agent Substances 0.000 abstract 1
- 230000000949 anxiolytic effect Effects 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 125000004193 piperazinyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/22—Nitrogen and oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU0103912A HU227237B1 (en) | 2001-09-27 | 2001-09-27 | Substituted alkylpyridazinone derivatives, process for their preparation, pharmaceutical compositions containing them |
| PCT/HU2002/000096 WO2003027097A1 (en) | 2001-09-27 | 2002-09-26 | Substituted alkylaminopyridazinone derivatives, process for the preparation thereof and pharmaceutical composition containing the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1430047T3 true DK1430047T3 (da) | 2005-06-06 |
Family
ID=89979721
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK02767729T DK1430034T3 (da) | 2001-09-27 | 2002-09-26 | Substituerede alkylaminopyridazinonderivater, fremgangsmåde til fremstilling deraf og en farmaceutisk sammensætning indeholdende disse |
| DK02762620T DK1430047T3 (da) | 2001-09-27 | 2002-09-26 | Substituerede alkylaminopyridazinonderivater, fremgangsmåde til fremstilling deraf og en farmaceutisk sammensætning indeholdende disse |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK02767729T DK1430034T3 (da) | 2001-09-27 | 2002-09-26 | Substituerede alkylaminopyridazinonderivater, fremgangsmåde til fremstilling deraf og en farmaceutisk sammensætning indeholdende disse |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US6930110B2 (enExample) |
| EP (2) | EP1430034B1 (enExample) |
| JP (2) | JP4472337B2 (enExample) |
| KR (2) | KR100911069B1 (enExample) |
| CN (3) | CN1325489C (enExample) |
| AT (2) | ATE288899T1 (enExample) |
| AU (2) | AU2002328166B2 (enExample) |
| BR (2) | BR0212839A (enExample) |
| CA (2) | CA2461510C (enExample) |
| CZ (2) | CZ2004528A3 (enExample) |
| DE (2) | DE60202969T2 (enExample) |
| DK (2) | DK1430034T3 (enExample) |
| EA (2) | EA006392B1 (enExample) |
| ES (2) | ES2237696T3 (enExample) |
| HU (1) | HU227237B1 (enExample) |
| MA (2) | MA27137A1 (enExample) |
| MX (2) | MXPA04002838A (enExample) |
| NO (2) | NO326370B1 (enExample) |
| NZ (2) | NZ532103A (enExample) |
| PL (2) | PL369256A1 (enExample) |
| PT (2) | PT1430047E (enExample) |
| SI (2) | SI1430034T1 (enExample) |
| SK (2) | SK1892004A3 (enExample) |
| WO (2) | WO2003027097A1 (enExample) |
| ZA (2) | ZA200402544B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60231507D1 (de) | 2001-07-20 | 2010-07-01 | Psychogenics Inc | Behandlung von hyperaktivitätsstörungen und aufmerksamkeitsdefiziten |
| HU227592B1 (en) * | 2002-11-13 | 2011-09-28 | Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag | Use of substituted alkyl-piridazinone derivatives for the treatment of memory decline and learning malfunctions |
| KR20100049500A (ko) * | 2007-03-15 | 2010-05-12 | 쉐링 코포레이션 | 글루칸 신타제 억제제로서 유용한 피리다지논 유도체 |
| JP6942896B2 (ja) * | 2018-04-30 | 2021-09-29 | ライボン・セラピューティクス・インコーポレイテッドＲｉｂｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | Ｐａｒｐ７阻害剤としてのピリダジノン |
| CN109053693B (zh) | 2018-09-20 | 2021-02-05 | 顺毅股份有限公司 | 哒嗪胺类化合物的制备及其应用 |
| US12371421B2 (en) | 2019-04-29 | 2025-07-29 | Ribon Therapeutics, Inc. | Solid forms of a PARP7 inhibitor |
| WO2022188889A1 (zh) * | 2021-03-12 | 2022-09-15 | 杭州英创医药科技有限公司 | 作为parp7抑制剂的化合物 |
| CN115490671B (zh) * | 2022-10-21 | 2024-05-14 | 水木未来(北京)科技有限公司 | Parp7抑制剂及其制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH557820A (de) * | 1970-11-12 | 1975-01-15 | Sandoz Ag | Verfahren zur herstellung von neuen 2-(2-hydroxyalkyl)4,5-dihydro-pyridazin (2h)-3-onen. |
| IE62890B1 (en) * | 1988-12-06 | 1995-03-08 | Hafslund Nycomed Pharma | New piperazinylalkyl-3(2h)-pyridazinones process for the preparation thereof and the use thereof as agents lowering blood pressure |
| PL164079B1 (pl) * | 1990-06-15 | 1994-06-30 | Akad Medyczna | posób wytwarzania nowych 2-amlnoalkilopochodnych 5-aminometyleno-6-/p-chlorofenylo /-4,5-dihydro-2H- plrydazyn -3-onu |
| HU209388B (en) * | 1990-12-27 | 1994-05-30 | Richter Gedeon Vegyeszet | Process for producing new 3/2h/-pyridazinones and pharmaceutical compositions comprising same |
| HU214320B (hu) * | 1991-12-20 | 1998-03-02 | EGIS Gyógyszergyár Rt. | Eljárás új 3(2H)-piridazinon-származékok és ezeket tartalmazó gyógyszerkészítmények előállítására |
| HU224067B1 (hu) * | 1995-05-29 | 2005-05-30 | Gyógyszerkutató Intézet Kft. | 3(2H)-Piridazinon-származékok és e vegyületeket tartalmazó gyógyszerkészítmények |
| CN1205190C (zh) * | 1998-06-05 | 2005-06-08 | 埃吉斯药物工厂 | 制备3(2h)－哒嗪酮－4－取代氨基－5－氯－衍生物的方法 |
-
2001
- 2001-09-27 HU HU0103912A patent/HU227237B1/hu not_active IP Right Cessation
-
2002
- 2002-09-26 DK DK02767729T patent/DK1430034T3/da active
- 2002-09-26 EP EP02767729A patent/EP1430034B1/en not_active Expired - Lifetime
- 2002-09-26 DE DE60202969T patent/DE60202969T2/de not_active Expired - Lifetime
- 2002-09-26 CN CNB028204425A patent/CN1325489C/zh not_active Expired - Fee Related
- 2002-09-26 SK SK1892004A patent/SK1892004A3/sk unknown
- 2002-09-26 US US10/491,151 patent/US6930110B2/en not_active Expired - Fee Related
- 2002-09-26 CA CA002461510A patent/CA2461510C/en not_active Expired - Fee Related
- 2002-09-26 WO PCT/HU2002/000096 patent/WO2003027097A1/en not_active Ceased
- 2002-09-26 CN CNB028189752A patent/CN100368404C/zh not_active Expired - Fee Related
- 2002-09-26 SI SI200230107T patent/SI1430034T1/xx unknown
- 2002-09-26 JP JP2003530685A patent/JP4472337B2/ja not_active Expired - Lifetime
- 2002-09-26 BR BR0212839-0A patent/BR0212839A/pt not_active IP Right Cessation
- 2002-09-26 AT AT02767729T patent/ATE288899T1/de not_active IP Right Cessation
- 2002-09-26 PL PL02369256A patent/PL369256A1/xx unknown
- 2002-09-26 AU AU2002328166A patent/AU2002328166B2/en not_active Ceased
- 2002-09-26 SK SK1902004A patent/SK1902004A3/sk unknown
- 2002-09-26 ES ES02767729T patent/ES2237696T3/es not_active Expired - Lifetime
- 2002-09-26 KR KR1020047004607A patent/KR100911069B1/ko not_active Expired - Fee Related
- 2002-09-26 NZ NZ532103A patent/NZ532103A/en unknown
- 2002-09-26 EA EA200400469A patent/EA006392B1/ru not_active IP Right Cessation
- 2002-09-26 DK DK02762620T patent/DK1430047T3/da active
- 2002-09-26 DE DE60202970T patent/DE60202970T2/de not_active Expired - Lifetime
- 2002-09-26 NZ NZ532104A patent/NZ532104A/en unknown
- 2002-09-26 CZ CZ2004528A patent/CZ2004528A3/cs unknown
- 2002-09-26 MX MXPA04002838A patent/MXPA04002838A/es active IP Right Grant
- 2002-09-26 PT PT02762620T patent/PT1430047E/pt unknown
- 2002-09-26 EP EP02762620A patent/EP1430047B1/en not_active Expired - Lifetime
- 2002-09-26 CZ CZ2004532A patent/CZ2004532A3/cs unknown
- 2002-09-26 WO PCT/HU2002/000097 patent/WO2003027078A1/en not_active Ceased
- 2002-09-26 PT PT02767729T patent/PT1430034E/pt unknown
- 2002-09-26 PL PL02369107A patent/PL369107A1/xx not_active IP Right Cessation
- 2002-09-26 BR BR0212932-9A patent/BR0212932A/pt not_active IP Right Cessation
- 2002-09-26 EA EA200400470A patent/EA006942B1/ru not_active IP Right Cessation
- 2002-09-26 AT AT02762620T patent/ATE288910T1/de not_active IP Right Cessation
- 2002-09-26 AU AU2002330656A patent/AU2002330656B9/en not_active Ceased
- 2002-09-26 KR KR1020047004606A patent/KR100890667B1/ko not_active Expired - Fee Related
- 2002-09-26 JP JP2003530669A patent/JP2005508914A/ja active Pending
- 2002-09-26 US US10/490,959 patent/US20050043314A1/en not_active Abandoned
- 2002-09-26 ES ES02762620T patent/ES2237690T3/es not_active Expired - Lifetime
- 2002-09-26 CA CA002461467A patent/CA2461467A1/en not_active Abandoned
- 2002-09-26 SI SI200230109T patent/SI1430047T1/xx unknown
- 2002-09-26 CN CN200710104934XA patent/CN101099740B/zh not_active Expired - Fee Related
- 2002-09-26 MX MXPA04002836A patent/MXPA04002836A/es active IP Right Grant
-
2004
- 2004-03-24 MA MA27588A patent/MA27137A1/fr unknown
- 2004-03-24 MA MA27589A patent/MA27068A1/fr unknown
- 2004-03-31 ZA ZA200402544A patent/ZA200402544B/en unknown
- 2004-03-31 ZA ZA200402545A patent/ZA200402545B/en unknown
- 2004-04-16 NO NO20041551A patent/NO326370B1/no not_active IP Right Cessation
- 2004-04-26 NO NO20041704A patent/NO325080B1/no not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0100615A2 (hu) | Szubsztituált 2-(2,6-dioxo-3-fluoro-piperidin-3-il)-izoindolinok és ezek alkalmazása TNFalfa-szint csökkentésére | |
| HUP0402311A2 (hu) | Naftiridinszármazékok, eljárás előállításukra, és alkalmazásuk foszfodiészteráz izoenzim 4 (PDE4) gátló hatóanyagként és ezeket tartalmazó gyógyszerkészítmények | |
| AP2003002841A0 (en) | Quinazolines as MMP-13 inhibitors | |
| NO903851D0 (no) | Fremgangsmaate for fremstilling av n-substituerte-4-pyrimidinaminer og -pyrimidindiaminer, og deres anvendelse som medikamenter. | |
| ATE394383T1 (de) | Biphenylkarbonsäureamidderivate als p38 kinase- inhibitoren | |
| HUP0300920A1 (hu) | Szubsztituált benzidszármazékok és gyógyszerként történő felhasználásuk | |
| HUP0204354A2 (hu) | Új heterociklusos vegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| DK1430047T3 (da) | Substituerede alkylaminopyridazinonderivater, fremgangsmåde til fremstilling deraf og en farmaceutisk sammensætning indeholdende disse | |
| GB0223232D0 (en) | Chemical compounds | |
| HUP0402033A2 (hu) | 2-Amino-4-piridil-metil-tiazolin-származékok alkalmazása az indukálható NO-szintetáz inhibitoraként, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| ATE337827T1 (de) | N-aryl-4,5-diaminopyrazole und diese verbindungen enthaltende färbemittel | |
| HUP0301553A2 (hu) | Gyógyászati készítmények és alkalmazásuk neurológiai rendellenességek kezelésére | |
| PL371520A1 (en) | New piperidinyl-alkylamino-pyridazinone derivatives, a process for the preparation thereof and pharmaceutical compositions containing said compounds | |
| HUP0302258A2 (hu) | Fenoxifenil-alkánszulfonátok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| DE602005015223D1 (de) | 3-(((4-phenyl)-piperazin-1-yl)-alkyl)-3-alkyl-1,3-dihydro-2h-indol-2-on-derivate und verwandte verbindungen zur behandlung von erkrankungen des zentralnervensystems | |
| IS7034A (is) | Díhýdróimidazó [5,1-A-] -SG(b)-karbólínafleiður, aðferð til framleiðslu þeirra og notkun sem lyf | |
| EA200100156A2 (ru) | Новые производные 6-сульфамоил-3-хинолилфосфоновой кислоты, способ их получения и содержащие их фармацевтические композиции | |
| DE60239324D1 (de) | Phenyl- und pyridyl-piperidine mit tnf-wirkung | |
| GB0223234D0 (en) | Chemical compounds | |
| TH49399A (th) | อนุพันธ์ของกรด 8-ออกโซ-5, 8-ไดไฮโดร-6H-ไดเบนโซ [a, g] ควินโนลิซีน-13-โพรพาโนอิก, การเตรียมอนุพันธ์ของมันเหล่านั้น และการประยุกต์ใช้งานของอนุพันธ์ดังกล่าวเหล่านั้นในการบำบัดรักษาโรค |